Scenario analysis of base-case results and NMBs assuming no adverse events from iron or RBC supplementation
| Strategy . | Cost . | Incremental cost . | Effectiveness (QALY) . | Incremental effectiveness (QALY) . | NMB . | iNMB (95% credible interval) . |
|---|---|---|---|---|---|---|
| Base-case model (health system perspective) | ||||||
| Bevacizumab | $428 000 | — | 9.3 | 1.0 | $973 000 | $432 000 (215 000-941 000) |
| SOC | $700 000 | $272 000 | 8.3 | — | $541 000 | |
| Base-case model (societal perspective) | ||||||
| Bevacizumab | $435 000 | — | 9.3 | 1.0 | $967 000 | $443 000 (218 000-973 000) |
| SOC | $717 000 | $282 000 | 8.3 | — | $524 000 | |
| Strategy . | Cost . | Incremental cost . | Effectiveness (QALY) . | Incremental effectiveness (QALY) . | NMB . | iNMB (95% credible interval) . |
|---|---|---|---|---|---|---|
| Base-case model (health system perspective) | ||||||
| Bevacizumab | $428 000 | — | 9.3 | 1.0 | $973 000 | $432 000 (215 000-941 000) |
| SOC | $700 000 | $272 000 | 8.3 | — | $541 000 | |
| Base-case model (societal perspective) | ||||||
| Bevacizumab | $435 000 | — | 9.3 | 1.0 | $967 000 | $443 000 (218 000-973 000) |
| SOC | $717 000 | $282 000 | 8.3 | — | $524 000 | |
Bevacizumab remains a cost-saving treatment even when the rates of adverse events from iron and RBC supplementation are reduced to 0.